1. Home
  2. PHAR vs CCNE Comparison

PHAR vs CCNE Comparison

Compare PHAR & CCNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAR
  • CCNE
  • Stock Information
  • Founded
  • PHAR 1988
  • CCNE 1865
  • Country
  • PHAR Netherlands
  • CCNE United States
  • Employees
  • PHAR N/A
  • CCNE N/A
  • Industry
  • PHAR Biotechnology: Pharmaceutical Preparations
  • CCNE Major Banks
  • Sector
  • PHAR Health Care
  • CCNE Finance
  • Exchange
  • PHAR Nasdaq
  • CCNE Nasdaq
  • Market Cap
  • PHAR 718.1M
  • CCNE 455.3M
  • IPO Year
  • PHAR N/A
  • CCNE N/A
  • Fundamental
  • Price
  • PHAR $11.00
  • CCNE $22.89
  • Analyst Decision
  • PHAR Strong Buy
  • CCNE Hold
  • Analyst Count
  • PHAR 3
  • CCNE 1
  • Target Price
  • PHAR $30.00
  • CCNE $25.00
  • AVG Volume (30 Days)
  • PHAR 3.0K
  • CCNE 61.0K
  • Earning Date
  • PHAR 07-31-2025
  • CCNE 07-17-2025
  • Dividend Yield
  • PHAR N/A
  • CCNE 3.15%
  • EPS Growth
  • PHAR N/A
  • CCNE N/A
  • EPS
  • PHAR N/A
  • CCNE 2.34
  • Revenue
  • PHAR $320,708,000.00
  • CCNE $219,886,000.00
  • Revenue This Year
  • PHAR $13.31
  • CCNE $17.91
  • Revenue Next Year
  • PHAR $7.68
  • CCNE $27.71
  • P/E Ratio
  • PHAR N/A
  • CCNE $9.78
  • Revenue Growth
  • PHAR 24.13
  • CCNE 1.97
  • 52 Week Low
  • PHAR $6.65
  • CCNE $18.90
  • 52 Week High
  • PHAR $12.61
  • CCNE $29.29
  • Technical
  • Relative Strength Index (RSI)
  • PHAR 51.11
  • CCNE 60.13
  • Support Level
  • PHAR $10.23
  • CCNE $22.30
  • Resistance Level
  • PHAR $11.21
  • CCNE $22.96
  • Average True Range (ATR)
  • PHAR 0.27
  • CCNE 0.55
  • MACD
  • PHAR -0.14
  • CCNE 0.11
  • Stochastic Oscillator
  • PHAR 34.01
  • CCNE 91.77

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About CCNE CNB Financial Corporation

CNB Financial Corp is providing integrated financial solutions, which create value for both consumers and businesses. These solutions encompass deposit accounts, private banking, real estate, commercial, industrial, residential and consumer loans and lines of credit, credit cards, treasury services, online banking, mobile banking, merchant credit card processing, remote deposit and accounts receivable handling. It derives revenue through the operations as a full-service bank engaging in a full range of banking activities and services, including trust and wealth management services, for individual, business, governmental, and institutional customers. The company branch are located in Pennsylvania, Ohio, New York and Virginia.

Share on Social Networks: